Aileron secures $40 million from big pharma investors
This article was originally published in Scrip
Executive Summary
Aileron Therapeutics, a private US biotech company, has secured $40 million in a series D financing round that included the investment arms of four of the world's largest pharmaceutical companies: GlaxoSmithKline, Novartis, Lilly and Roche.